The fracture risk assessment tool (FRAXTM), where one is in Tunisia ?

##plugins.themes.academic_pro.article.sidebar##

Published Feb 4, 2011
Download
pdf
Vol. 89 No. 2 (2011): Issue Feb 2011

##plugins.themes.academic_pro.article.main##

Saoussen Zrour-Hassen
Mahbouba Jguirim
Mohsen Guezguez
Hichem Mnif
Mohamed Younes
Ismail Béjia
Mongi Touzi
Abderrazek Abid
Habbib Essabah
Naceur Bergaoui

Abstract

Background: The fracture risk assessment tool (FRAXTM), published in February 2008, is developed based on the use of clinical risk factors with or without bone mineral density tests.
Aim : To calculate the FRAX tool in a cohort of Tunisian patients in whom bone mineral density (BMD) was assessed by dual X ray absorptiometry (DXA); to correlate this score to osteoporotic fracture and to BMD assessment and to propose a threshold for therapeutic intervention
Methods: In a cross sectional study of 582 patients older than 40 years, in whom a BMD measurement by DXA has been performed between January 2006 and December 2009, clinical risk factor for osteoporotic fracture and the occurrence of a prior fragility fracture were assessed.
The French version of the FRAX tool was used. Threshold for pharmacological intervention was evaluated by ROC curve.
Results : Patients were aged 62.3±10.4 years. They were female in 91.2% of cases. BMD measurement was under 2.5 standard deviation in 53.2%. Osteopenia was noted in 29.2% of cases and BMD was normal in 17.4 % of cases. Osteoporotic fractures were observed in 38.2% of cases. Major osteoporotic fractures (FOM) (hip, vertebra, radius occurred in 82% of cases. The FRAX® score calculated with T-score was 8.55 ± 8.54% for the FOM and 3.02 ± 6.37% for femoral neck (FN), while it was 7.81 ± 6.45% for the FOM and 2.58 ± 3.97% for the FN if calculated without T-score with a significant difference (p <10-3). For the patients having T-score under 2.5 SD, FRAX score was 11.39 ± 10.32% for the FOM and 4.74 ± 8.13% for the FN if calculated with T-score and it was 9.18 ± 6.95 % for the FOM and 3.19 ± 4.11 % if calculated without T-score. The score FRAX was correlated to BMD (r=0,53, p <10-3) and to fracture prevalence (p < 10-3). The threshold of therapeutic intervention was fixed to 30% for the FOM and 7% for the FN.
Conclusion: Our study confirms the usefulness of the FRAX score in the prediction of fracture risk in Tunisian population. The determination of therapeutic threshold intervention requires other prospective and larger studies with medico-economic analyses.

Keywords:

Osteoporosis, bone fracture, densitometry, risk factors, absorptiometry

##plugins.themes.academic_pro.article.details##

References

  1. Boonen S, Dejaeger E, Vanderschueren D, et al. Osteoporosis and osteoporotic fracture occurrence and prevention in the eldery: a geriatric perspective. Best Pract Res Clin Endocrinol Met 2008;22:765-85.
  2. Fardellone P. Comment évaluer le risque fracturaire en 2008. Rev Rhum 2008;75;931-4.
  3. Sahli H, Testouri N, Ben Chihaouia M, et al. Bone mineral density in healthy Tunisian women. Maturitas 2009;63:227-32.
  4. Sellami S, Sahli H, Meddeb N, et al. Prévalence des fractures ostéoporotiques chez la femme tunisienne. Rev Chir Orthop Reparatrice Appar Mot. 2006;92:490-4.
  5. World Health Organization. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. WHO technical report series. Geneva:WHO, 1994.
  6. Holroyd C, Cooper C, Dennison E. Epidemiology of osteoporosis. Best Pract Res Endocrinol Met 2008;22:671-85.
  7. Marshall D, Johnell O, Wedel H, et al. Meta-analysis of how well measures of bone mineral density predict occurence of osteoporotic fractures. Br Med J 1996;312:1254-9.
  8. Kanis JA, Borgstrom F, Zethraeus N, et al. Intervention thresholds for osteoporosis in the UK. Bone. 2005;36:22-32
  9. Dargent-Molina P, Faires F, Grandjean H, et al. Fall related factors and risk of hip fracture: the EPIDOS prospective study. Lancet. 1996;348:145-9
  10. Roux C, Briot K, Horlait S, et al. Assessment of non-vertebral fracture risk in postmenopausal women. Ann Rheum Dis 2007;66:931-5.
  11. Roux C, Thomas T. Du bon usage du FRAX. Rev Rhum 2009; 76: 1-3.
  12. Kanis JA, Johnell O, Oden A, et al. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int, 2008; 19: 85-97.
  13. Johnell O, Kanis JA, Oden A, et al. Predictive value of bone mineral density for hip and other fractures. J Bone Miner Res 2005;20:1185-94.
  14. Kanis JA. Diagnosis of osteoporosis and assessment of fracture risk. Lancet 2002;359:1929-36.
  15. Kanis JA, Borgstrom F, De Laet C, et al. Assessment of fracture risk. Osteoporos Int 2005;16:581-9.
  16. Kanis JA, Oden A, Johnell O, et al. The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int. 2007;18:1033-46.
  17. Johansson H, Kanis J A, Oden A, et al. BMD, clinical risk factors and their combination for hip fracture prevention. Osteoporos Int 2009;20:1675-82.
  18. Curran D, Maravic M, Kiefer P, et al. Epidemiology of osteoporosis-related fractures in France: A literature review. Joint Bone Spine. 2010;77:546-51.
  19. C Roux, B Cortet. FRAX: résultats chez les femmes ménopausées ostéoporotiques francaises. Rev Rhum 2008;75:949-953.
  20. Francis R.M. Fracture risk assessment. Current Orthopaedics, 2008; 22:322-7.
  21. Leslie W D, Tsang J F, Lix L M. Validation of ten-year fracture risk prediction: A clinical cohort study from the Manitoba Bone Density Program. Bone 2008, 43:667-671.
  22. Lippuner K, Johansson H, Kanis JA, et al. FRAX® assessment of osteoporotic fracture probalility in Switzerland. Osteoporos Int 2010;21:381-9.
  23. Lippuner K, Johansson H, Kanis JA et al. Remaining lifetime and absolute 10-year probabilities of osteoporotic in Swiss men and women. Osteoporos Int 2009;20:1131-40.
  24. Fujiwara S, Nakamura T, Orimo H, et al. Development and application of a Japanese model of the WHO fracture risk assessment tool (FRAXTM). Osteoporos Int 2008; 19: 429-35.
  25. Tsang S W, Kung A W, Kanis J A, et al. Ten-year fracture probability in Hong Kong Southern Chinese according to age and BMD femoral neck T-scores. Osteoporos Int 2009;20:1939-45.
  26. Sandhu S K, Nguyen N D, Center J R, et al. Prognosis of fracture:evaluation of predictive accuracy of the FRAXTM algorithm and Garvan nomogram. Osteoporos Int 2010;21:863-71.
  27. Curtis J R, McClure L A, Delzell E, et al. Population based fracture risk assessment and osteoporosis treatment disparities by race and gender. J Gen Intern Med 2009;24:956-62.
  28. Kanis JA, Johnell O, Oden A, et al. FRAXTM and the assessment of fracture probability in men and women from the UK. Osteoporos Int. 2008;19:385-97
  29. Adler RA, Hastings FW, Petkov VL. Treatment thresholds for osteoporosis in men on androgen deprivation therapy: T-score versus FRAXTM. Osteoporos Int 2010;21:647-53.
  30. McCloskey EV, Johansson H, Oden A, et al. Ten-year fracture probability identifies women who will benefit from clodronate therapy-additional results from a double-blind, placebocontrolled randomised study. Osteoporos Int 2009;20:811-7.
  31. Tosteson ANA, Melton III L.J, Dawson-Hughest B, et al. Costeffective osteoporosis treatment threshold : the united states perspective. Osteoporos Int. 2008;19:437-47.
  32. Dawson-Hughes B, Tosteson AN, Melton L.J 3rd, et al . L. Implications of absolute fracture risk assessment for osteoporosis practice guidelines in USA. Osteoporos Int. 2008;19:449-58.
  33. Borgström F, Ström O, Coelho J, et al. The cost-effectiveness of risedronate in the UK for the management of osteoporosis using the FRAX. Osteoporos Int. 2010;21:495-505.
  34. Borgström F, Ström O, Coelho J, et al. The cost-effectiveness of strontium ranelate in the UK for the management of osteoporosis. Osteoporos Int. 2010;21:339-49.
  35. Kanis JA, McCloskey EV, Johansson H, et al. National osteoporosis Guideline Group. Case finding for the management of osteoporosis with FRAX®-assessment and intervention thresholds for the UK. Osteoporos Int 2008;19:1395-408.
  36. Roux C, Thomas T. Du bon usage du FRAX®. Rev Rhum 2009 ;76: 1-3.
  37. Compston J, Cooper A, Cooper C, et al, on behalf of the National Osteoporosis Guideline Group (NOGG). Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK. Maturitas, 2009,62;105-108.
  38. Kanis J A, Oden A, Johansson H, et al. FRAX® and its applications to clinical practice. Bone 2009;44:734-43.